Sponsored by:
B HIV Grand Rounds from the
University of Pennsylvania
2011- 2012
The Feasibility of Modulating Cellular DNA Mutating Enzymes as Next-generation HIV / AIDS Therapeutics
January 12, 2012 12:00 PM
John Morgan Class of 62 Auditorium
Reuben S. Harris PhD
Associate Professor, Department of
Biochemistry, Molecular Biology and Biophysics
University of Minnesota
Minneapolis, Minnesota
Target Audience
This program has been designed for HIV specialists, Infectious Disease specialists, Internal Medicine specialists, Family Practice
physicians, Dermatologists, Ostio-specialists, Nephrologists, Hematology/oncologist, Psychiatrists, Public Health professionals,
OB/GYN physicians and other clinicians interested and involved in the care of patients with HIV/AIDS.
General Goals and Learning Objectives for Series
After completing this activity, participants should be able to:
 List the important factors that play a role in ARV therapy success;
 Explain the role that drug adverse events, drug pharmacokinetics and patient adherence play in achieving ARV success and
avoiding morbidity and mortality;
 Describe the important opportunistic infections and co-morbidities that may affect HIV-positive patients and increase their
risk for morbidity and mortality;
 Discuss the importance of individualizing the care of each HIV-positive patient.
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing
Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA
Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgement of Commercial Support
Supported by educational grants from: Gilead Sciences and Janssen Therapeutics.
Obtaining CME Credit
To get credit for today’s event, please use the SMS Phone number below and enter the Event code displayed.
•
•
SMS number: 95495
Event code: PENNCME DEEPBUNK
If you desire CME credit for viewing this session, and have not established a UPenn CME account, please proceed to
http://penncmeonline.com/user/register. Create your account and then you will receive an email with your initial login information.
Follow the link in the email to change your password and complete the one-time profile set up. Once this is finished, your UPenn
CME account will enable you to receive credit for this and all subsequent sessions by simply texting the session specific CME code
following each grand rounds.
For more information, please contact: Richard Gordon at: 856-506-5790 or email at: admin@viraled.com
Check your CME online at www.med.upenn.edu/cme
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania and ViralEd, LLC for individuals who are in a
position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have
with any commercial interest that provides products or services that may be relevant to the content of this continuing medical
education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial
relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and free of
commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to
the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their
presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the University of Pennsylvania School of Medicine (Rodman Campbell, Mila Kostic, Belinda
Rose, and Mindy Pollock Troy), our educational partner ViralEd, LLC (Rick Gordon, Brian Boyle, MD, JD and Ed Hettman), and
the peer reviewer, Zalman Agus, MD, Associate Dean for Continuing Medical Education, have reported that they have no
relevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the
content of this educational activity:
FACULTY NAME
John Bartlett, MD
Reuben S. Harris, PhD
The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of
this educational activity.
FACULTY NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
Calvin Cohen, MD
Gilead; Bristol-Myers Squibb: Merck & Co.; Tibotec; ViiV
Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; Abbott
Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec
Contracted Research
Consulting Fees
Speakers Bureaus
Ian Frank, MD
GlaxoSmithKline, Merck & Co.
Gilead, Tibotec
Gilead, Tibotec (both ceased Sept. 2010)
Contracted Research
Consulting Fees
Speakers Bureaus
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary,
royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership
interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as
employment, management position, independent contractor (including contracted research), consulting, speaking and teaching,
membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or
expected
DISCLOSURE OF UNAPPROVED USES OF PRODUCTS
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the
FDA. ViralEd, LLC, the Perelman School of Medicine at the University of Pennsylvania, Gilead Sciences and Janssen
Therapeutics do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of ViralEd,
LLC, the Perelman School of Medicine at the University of Pennsylvania, Gilead Sciences and Tibotec Therapeutics. Please refer
to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.